$NVAX just threw a curveball with its Q3 results. They beat expectations and surprised a few folks on the upside, which isn’t something you hear every day from biotech names with a rough past few years. This kind of surprise quarter can shake off some of the negativity and give traders something real to chew on, especially since NVAX’s been trying to reset its narrative after the pandemic vaccine boom faded. Now the question is whether this beat is a one-off bounce or the start of something more stable. You think $NVAX just caught a lucky break, or is this the beginning of a legit turnaround?